Objective: To examine the associations of the serum cystatin C level and chronic kidney disease with the incidence of age-related macular degeneration (AMD) over 15 years.
Conclusion: There is a relationship between the level of serum cystatin C and chronic kidney disease with the incidence of AMD. The underlying biological processes remain to be determined.
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T HE FINDING OF A RELATIONship of complement factor H Y402H (1277T→ C) genotype status to both agerelated macular degeneration (AMD) and kidney disease (membranoproliferative glomerulonephritis type II and hemolytic uremic syndrome) has led to speculation that kidney disease might be associated with AMD. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Furthermore, many factors associated with chronic kidney disease (CKD) such as oxidative stress, inflammation, and endothelial dysfunction have been hypothesized to have a role in the pathogenesis of AMD. [17] [18] [19] [20] [21] [22] [23] [24] However, there are few and inconsistent epidemiological data about the relationship of CKD to AMD. [25] [26] [27] Serum cystatin C has been used to estimate glomerular filtration rate to define the presence of CKD. 28, 29 It is abundant in retinal pigment epithelium (RPE) cells and has been hypothesized through its effects on cathepsins to have a role in the pathogenesis of AMD. 30, 31 To our knowledge, no population-based epidemiological studies have examined the association of the level of serum cystatin C with AMD. In the present study, we examined the relationship of serum blood urea nitrogen (BUN), cystatin C, gross proteinuria, and CKD to the incidence and progression of AMD during 15 years of follow-up in the Beaver Dam Eye Study. pants who were examined at the baseline and 5-and 10-year follow-up examinations, 2119 (85.4%) participated in the 15-year follow-up examination (March 31, 2003 , through April 30, 2005 Comparisons between participants and nonparticipants at the baseline and 5-, 10, and 15-year follow-up examinations are reported elsewhere. [33] [34] [35] [36] Adjusting for age, sex, and other risk factors, individuals with higher levels of serum cystatin C were more likely to die (data not shown). Severity of AMD did not affect the relationship of the serum cystatin C level to participation or death (data not shown).
PROCEDURES AND DEFINITIONS
Similar procedures, used at both the baseline and follow-up examinations, are described in detail elsewhere. [37] [38] [39] [40] [41] [42] [43] [44] [45] Informed consent was obtained from each participant at the beginning of the examination. Pertinent parts of the examination at both baseline and follow-up consisted of measurement of height and weight and taking of stereoscopic 30°color fundus photographs centered on the macula (Diabetic Retinopathy Study standard field 2). The Wisconsin Age-Related Maculopathy Grading System was used to assess the presence and severity of lesions associated with AMD. 38, 39 Grading procedures, lesion descriptions, and detailed definitions of the presence and severity of specific AMD lesions have been reported elsewhere. [38] [39] [40] [41] [42] [43] Early AMD was defined by the presence of either soft indistinct drusen or any type of drusen associated with RPE depigmentation or increased retinal pigment. Incidence of early and late AMD and component lesions was defined by their presence at followup in either eye when absent at the previous examination. For each eye, a 6-level severity scale for AMD has been defined elsewhere. 44 In brief, level 1 is equivalent to having no AMD, levels 2 through 4 indicate lesions defining early AMD of increasing severity (by type, size, area of drusen, and presence of pigmentary abnormalities), and levels 5 and 6 indicate lesions defining late AMD. Progression of AMD was defined as an increase in severity in either eye by 2 steps or more from levels 1 through 3 and 1 step or more from level 4 or 5 on the following AMD severity scale: Casual blood specimens were obtained at each examination. An aliquot of blood was used immediately for determination of the white blood cell count. Serum BUN was measured using a colorimetric method (the Berthelot reaction) on an automatic analyzer (RA-1000 AutoAnalyzer; Technicon Instruments Corp, Tarrytown, New York). Gross proteinuria concentration was determined using a dipstick on a casual urine sample and defined as 1ϩ or greater. Remaining serum was stored without preservative at −80°C in cryogenic vials with O-rings for up to 17 years until the vials were shipped on dry ice to the University of Minnesota Fairview Laboratory for the analyses reported herein. Serum creatinine concentration was measured using reflectance spectrophotometry on a chemistry analyzer (Vitros; Ortho Clinical Diagnostics, Inc, Rochester, New York). The laboratory coefficient of variability was 2.2%. The level of serum cystatin C was determined using a nephelometer (BN100; Dade Behring, Inc, Deerfield, Illinois). The interassay precision was determined at 2 control levels: 1.72 mg/L (coefficient of variability, 6.4%) and 0.78 mg/L (coefficient of variability, 5.2%). The glomerular filtration rate from serum creatinine was estimated using the validated MDRD (Modification of Diet in Renal Disease [Study]) prediction equation, which included age, sex, and race/ ethnicity. 46, 47 Mild CKD was defined as more than 45 mL /min/ 1.73 m 2 to 60 mL /min/1.73 m 2 or less, and moderate to severe CKD as 45 mL /min/1.73 m 2 or more using the MDRD equation. Cigarette smoking status was determined as follows: individuals were classified as nonsmokers if they had smoked fewer than 100 cigarettes in their lifetime, as ex-smokers if they had smoked more than 100 cigarettes in their lifetime but had stopped smoking before the examination, and as current smokers if they had not stopped smoking. Hypertension was defined as a mean systolic blood pressure of 140 mm Hg or higher, a mean diastolic blood pressure of 90 mm Hg or higher, having a history of hypertension, and use of antihypertensive medication at the time of the baseline examination. Individuals were classified as having diabetes if they had a history of diabetes mellitus and were being treated with insulin, oral hypoglycemic agents, or diet modification or had newly diagnosed diabetes at the baseline examination. Body mass index was defined as weight in kilograms divided by height in meters.
2 Current vitamin use was defined at 3 levels: no use, use of multivitamins, or use of other single or combinations of vitamins (eg, vitamin B complex).
STATISTICAL ANALYSES
For statistical analyses, we examined the relationships between serum cystatin C, creatinine, and BUN levels, the presence of gross proteinuria, and the presence of CKD to the incidence of early AMD, exudative AMD, geographic atrophy, and the progression of AMD. Commercially available software (SAS, version 9; SAS Institute, Inc, Cary, North Carolina) was used to analyze the data. Multivariate odds ratios (ORs) and 95% confidence intervals (CIs) were calculated from discrete linear logistic hazard models. 48 These analytical approaches enabled those individuals who were right censored (not seen after the 5-or 10-year examination because of death or nonparticipation) to contribute information to the estimates. 49 Models using timevarying covariates updated at each follow-up examination (ie, for each interval in which an individual participated), the values of the mild CKD at the beginning of the interval were used.
Analyses first controlled for age in 4 categories of approximately 10-year bands and for sex. We considered factors related to both the renal risk factors and AMD end points (eg, smoking history, white blood cell count, body mass index, vitamin use, and sedentary lifestyle) as potential confounders at multivariate analyses. Characteristics such as stroke, coronary heart disease, poor general health, and biochemical end points that were not related to both independent renal risk factors and incident AMD end points in our study were excluded as confounders.
The distributions of cystatin C, creatinine, and BUN levels were highly skewed; therefore, we modeled these after logtransforming the variables. We present ORs as a deviation increase in the risk factor for continuous measures. Interactions were tested only for cystatin C level and AMD status with CKD status (none or mild to severe).
RESULTS

BASELINE CHARACTERISTICS
Baseline characteristics of participants included and not included in analyses are given in Table 1 . Individuals without AMD incidence data were more likely to be older and, while controlling for age, were more likely to be current smokers, have a higher white blood cell count and a higher mean serum cystatin C level, and to have mild or severe CKD, and were less likely to have early AMD or hypertension at baseline compared with participants included in the analyses. Relationships of serum cystatin C level, serum BUN level, gross proteinuria, and CKD to sex and age are given in Table 2 . With the exception of gross proteinuria, all increased with age. After controlling for age, men had higher levels of serum cystatin C and BUN levels compared with women (PϽ.001 for all associations). Also, men exhibited a higher prevalence of proteinuria (PϽ.001) and a lower prevalence of CKD (P=Ͻ.001) compared with women.
CUMULATIVE INCIDENCE OF AMD
Of individuals at risk, 392 of 2825 developed incident early AMD, 63 of 3503 developed incident exudative AMD, 39 of 3489 developed geographic atrophy, and 400 of 3505 demonstrated progression of AMD. The 15-year cumulative incidence of early AMD was 14.3%; pure geographic atrophy, 1.3%; exudative AMD, 2.0%; and progression of AMD, 12.2%. The prevalence and 15-year cumulative incidence and progression of AMD were similar in men and women and increased with age (data not shown).
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BLOOD UREA NITROGEN LEVEL, SERUM CYSTATIN C LEVEL, GROSS PROTEINURIA, CKD, AND INCIDENCE OF AMD
While controlling for age and sex, smoking status, white blood cell count, body mass index, and history of vitamin use, BUN level, and the presence of gross proteinuria were not associated with the 15-year cumulative incidence of early AMD, exudative AMD, pure geographic atrophy, or progression of AMD ( Table 3) . Mild CKD was associated with the 15-year cumulative incidence of early AMD but not the incidence of exudative AMD and pure geographic atrophy or progression of AMD (Table 3) . Higher levels of serum cystatin C were associated with the 15-year cumulative incidence of early AMD and exudative AMD but not with the incidence of geographic atrophy or progression of AMD (Table 3) 
COMMENT
In the Beaver Dam Eye Study, when controlling for age, sex, smoking status, and other risk factors, a higher level of serum cystatin C was associated with increased risk of incident early AMD and exudative AMD. The effect was stronger for incident exudative AMD in individuals without CKD compared with those with CKD, which suggests that this relationship might not be due to kidneyrelated processes. To our knowledge, no other published articles from population-based studies have examined the relationship of the level of serum cystatin C with the incidence of AMD. The underlying reasons for our finding are not known.
Serum cystatin C is ubiquitous in the body, including human RPE. 50 Serum cystatin C is an inhibitor of cysteine proteinases (eg, the cathepsins B, L, and S) found in the eye. [51] [52] [53] It has been hypothesized that cathepsins are involved in the pathogenesis of AMD. 54 Data from cell culture and animal studies suggest that cathepsins may maintain homeostasis of the retinal photoreceptors and the extracellular environment of the Bruch membrane, including the release of antiangiogenic endostatins from Bruch membrane collagen XVIII. [55] [56] [57] Im et al 58 hypothesized that high levels of serum cystatin C may have both deleterious and protective effects on the angiogenic response in the eye through its regulation of cathepsins. The deleterious effect of a high serum cystatin C concentration is postulated to be due to its reduction of the protective effect of cathepsins in the release of antineogenic endostatins from Bruch membrane collagen, resulting in higher risk of exudative AMD. This is consistent with our findings. A protective effect of higher cellular levels of serum cystatin C is hypothesized to be due to its suppression of the vasculogenic effect of cathepsins at the level of the endothelium. This is consistent with the fact that B precursor cystatin C CST3 genotype variant on chromosome 20, thought to result in lower levels of serum cystatin C in the RPE, is related to a higher risk of earlier onset of exudative AMD in human beings. 59 However, to our knowledge, no data show that higher levels of serum cystatin C are associated with higher RPE cellular levels of cystatin C and that the latter result in changes in level and function of cathepsins in the aged human retina.
We hypothesized that CKD and its markers, including cystatin C, would be associated with increased risk of incident AMD. This was based on an earlier finding by us that complement factor H Y402H (1277T→C) genotype status is related to both progression of AMD and incidence of CKD. 16 We speculated that CKD would be associated through systemic inflammation and oxidative stress with an increase in the risk of incident AMD. In the Beaver Dam Eye Study, we found a statistically significant relationship of mild CKD with the incidence of early AMD but not with exudative AMD, geographic atrophy, or progression of AMD. This is consistent with data from 2 earlier studies that examined these relationships. 26 The strengths of our study include its high participation rate, long follow-up, and use of standardized protocols to measure CKD risk factors and AMD end points. However, any conclusions or explanations about associations or lack thereof described herein must be made with caution for several reasons. First, the concomitant low frequency of some risk factors (eg, CKD) and of the incidence of some lesions (eg, pure geographic atrophy) limit our ability to detect (or reject) meaningful relations. Second, some findings that may be of potential biological significance may be entirely owing to chance, given the number of associations examined. Third, it is possible that we did not find significant relationships between some risk factors and AMD because individuals with these factors (eg, CKD) who developed AMD did not live to participate in the follow-up examination. However, nonparticipation because of death is probably unlikely to have biased our findings because AMD was not associated with mortality in the Beaver Dam Eye Study cohort. 61 In addition, time-dependent covariate modeling for CKD showed similar strengths of association for CKD as those reported for the 15-year cumulative incidence of these end points. Fourth, there may have been misclassification of CKD. This might be expected to bias the results to the null. Fifth, there may have been uncontrolled confounding.
In conclusion, data from the Beaver Dam Eye Study show an association of the level of serum cystatin C and CKD with the incidence of AMD independent of smoking and other risk factors. Confirmation of these findings in other studies and a better understanding of the biological processes underlying our findings are needed. 
